Cargando…
The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
The major obstacle in platinum chemotherapy is the repair of platinum-damaged DNA that results in increased resistance, reduced apoptosis, and finally treatment failure. Our research goal is to determine and block the mechanisms of platinum resistance. Our recent studies demonstrate that several kin...
Autores principales: | Liang, Xiaobing, Guo, Yi, Figg, William Douglas, Fojo, Antonio Tito, Mueller, Michael D., Yu, Jing Jie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3265242/ https://www.ncbi.nlm.nih.gov/pubmed/22312557 http://dx.doi.org/10.1155/2011/715469 |
Ejemplares similares
-
Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001) -
γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
por: Rawlinson, Rebecca, et al.
Publicado: (2014) -
AR phosphorylation and CHK2 kinase activity regulates IR-stabilized AR–CHK2 interaction and prostate cancer survival
por: Ta, Huy Q, et al.
Publicado: (2020) -
Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer
por: Nair, Jayakumar, et al.
Publicado: (2020) -
Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022)